Arthroscopic shaver safety review
This article was originally published in The Gray Sheet
Executive Summary
FDA is encouraging surgical facilities to evaluate the adequacy of their cleaning procedures for arthroscopic shavers after becoming aware of instances where pieces of tissue remain within shavers after cleaning in accordance with manufacturer instructions. Retained tissue can compromise the sterilization process for the devices, which are used for tissue resection and bone debridement. The agency advises hospitals to be sure that all personnel responsible for cleaning the products comply with the manufacturer's instructions, carefully inspect the devices following cleaning, and report any problems with retained tissue in arthroscopic shavers through FDA's MedWatch safety and adverse event reporting system. In the July MedSun newsletter, the agency notes that the hospital that brought the problem to its attention is effectively inspecting its shavers after cleaning by looking at the channels of the shaver hand piece with a 3 mm scope
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.